Wisconsin Democrats plan to reintroduce a bill that would have created a prescription drug affordability board (PDAB) in the state next session, after the bill failed again this year.
FREE TRIAL Receive 30 days of no-obligation access. SIGN UP
The House Ways & Means Committee on Wednesday will mark up legislation to stretch out several pandemic-era telehealth flexibilities through 2026 and extend certain other Medicare hospital bonuses into 2025, and pay for the initiatives by reforming pharmacy benefit manager policies, phasing in changes to clinical lab pay over a longer period and extending adjustments to hospice pay.
Wisconsin Democrats plan to reintroduce a bill that would have created a prescription drug affordability board (PDAB) in the state next session, after the bill failed again this year.
FDA granted breakthrough device designation Tuesday (May 7) for an at-home diagnostic test for high-risk human papillomavirus (HPV), an alternative to traditional in-office screening the company expects to be covered by insurance plans as preventative care.
The Senate Budget Committee will hold a hearing Wednesday (May 8) that is expected to highlight draft legislation by Chair Sheldon Whitehouse (D-RI) calling for CMS to accelerate the transition from fee-for-service to value-based pay by creating “hybrid” payment models.
Nursing facilities could be subject to state investigations into cases of adult neglect and maltreatment, according to a final rule the Administration for Community Living unveiled Tuesday (May 7), though the Biden administration declined to nationally mandate which entities states must investigate and left the details up to local Adult Protective Services (APS).
The Senate health committee recently parsed ways lawmakers can help stem the ongoing maternal and infant mortality crisis -- coming as a new report from the Centers for Disease Control and Prevention shows some significant progress in reductions to those deaths.
FDA Commissioner Robert Califf told Inside Health Policy “it’s an open question right now” how the agency tackles drug makers’ use of artificial intelligence in drug development and suggested he hopes to use multiple public-private partnerships to tackle the issue.
HOT TOPICS
The White House science office has released a new policy on dual-use research that applies a higher standard of federal oversight requiring agencies that oversee such research to determine the risks outweigh the benefits and appropriate risk mitigations are in place, following a recommendation to enhance safety measures from federal science advisors last year. |
FDA's Office of New Drugs (OND) approved 55 new drugs in 2023, with a little over half of those drugs for rare diseases. |
The Congressional Budget Office (CBO) laid out the new research it needs to assess the budgetary effects were Medicare to widely cover anti-obesity medications (AOMs), specifically asking for data on near and long-term clinical impacts, factors affecting use of the drugs and the expectations around the price and effectiveness as they are being developed. |
The House is scheduled to vote under suspension of the rules Monday evening (May 6) on whether to pass two bills related to agencies’ practices for rules and guidances: one aimed at ensuring the best available scientific and economic data underpin regulatory policies and a second aimed at weeding out comments generated by AI. |
© 2002-2024. Inside Washington Publishers | Contact Us